Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KCNN4 | O15554 | 3/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.36 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6776986 | 0.90 | MEN1 (0.41) | TDP1MAPK1ALDH1A1ALOX15KMT2A | |
| SCHEMBL11584647 | 0.86 | TDP1 (0.38) | TDP1MAPK1ALDH1A1ALOX15MAPT | |
| SCHEMBL135668 | 0.82 | MAPK1 (0.56) | TDP1MAPK1ALDH1A1ALOX15MAPT | |
| SCHEMBL4169444 | 0.77 | MAPK1 (0.44) | MAPK1ALDH1A1ALOX15MAPTKMT2A | |
| Tert-Butyl Formate SCHEMBL28259773 | 0.77 | MAPK1 (0.68) | TDP1MAPK1ALDH1A1ALOX15MAPT | |
| SCHEMBL183490 | 0.76 | KIF11 (0.40) | TDP1MAPK1ALDH1A1ALOX15MAPT | |
| SCHEMBL3121099 | 0.76 | MAPK1 (0.43) | MAPK1ALDH1A1ALOX15MAPTKMT2A | |
| SCHEMBL4675623 | 0.75 | TDP1 (0.39) | TDP1MAPK1ALDH1A1ALOX15MAPT | |
| Tert-Butyl Formate SCHEMBL28106695 | 0.75 | TDP1 (0.81) | TDP1MAPK1ALDH1A1 | |
| Biphenyl SCHEMBL27794837 | 0.74 | TDP1 (0.62) | TDP1MAPK1ALDH1A1MAPTCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 620 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2788353-B1 | CAGE AMINE LIGANDS FOR METALLO-RADIOPHARMACEUTICALS | Clarity Pharmaceuticals Ltd (AU) | 2022-05-18 | — | — | EP | claimed |
| US-7432389-B2 | Compounds for the treatment of Alzheimer's disease | ELAN PHARMACEUTICALS, INC. (US) | 2008-10-07 | — | — | US | claimed |
| US-20060287306-A1 | Compounds to treat alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2006-12-21 | — | — | US | claimed |
| US-20060276642-A1 | Compounds to treat Alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2006-12-07 | — | — | US | claimed |
| US-20060211860-A1 | Compounds for the treatment of Alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2006-09-21 | — | — | US | claimed |
| EP-1666452-A2 | Compounds to treat Alzheimer's disease | Elan Pharmaceuticals, Inc. (US) | 2006-06-07 | — | — | EP | claimed |
| US-7030239-B2 | Compounds to treat Alzheimer's disease | ELAN PHARMACEUTICALS, INC. (US) | 2006-04-18 | — | — | US | claimed |
| EP-1299352-B1 | COMPOUNDS TO TREAT ALZHEIMER'S DISEASE | ELAN PHARM INC (US) | 2005-12-28 | — | — | EP | claimed |
| US-20040214846-A1 | Compounds to treat Alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2004-10-28 | — | — | US | claimed |
| US-20030013881-A1 | Compounds to treat Alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2003-01-16 | — | — | US | claimed |
| US-20020128255-A1 | Compounds to treat alzheimer's disease | PHARMACIA & UPJOHN COMPANY | 2002-09-12 | — | — | US | claimed |
| US-20020022623-A1 | Compounds to treat alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2002-02-21 | — | — | US | claimed |
| US-20020016320-A1 | Compounds to treat alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2002-02-07 | — | — | US | claimed |
| US-4826993-A | Substituted diazolidinones | ELI LILLY AND COMPANY (US) | 1989-05-02 | — | — | US | claimed |
| US-3944590-A | ALKYL PHENYL CARBONATES | CIBA-GEIGY CORPORATION (US) | 1976-03-16 | — | — | US | claimed |
| US-20240190897-A1 | NITROGEN-CONTAINING MACROCYCLIC CONJUGATES AS RADIOPHARMACEUTICALS | Clarity Pharmaceuticals Ltd (AU) | 2024-06-13 | — | — | US | disclosed |
| US-11905301-B2 | Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals | CLARITY PHARMACEUTICALS LTD. (AU) | 2024-02-20 | — | — | US | disclosed |
| US-4251517-A | FUNGICIDES | CIBA-GEIGY CORPORATION (US) | 1981-02-17 | — | — | US | disclosed |
| US-4145344-A | BICYCLOMYCIN DERIVATIVES | CIBA-GEIGY CORPORATION (US) | 1979-03-20 | — | — | US | disclosed |
| US-3944590-A | ALKYL PHENYL CARBONATES | CIBA-GEIGY CORPORATION (US) | 1976-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214846-A1 | Compounds to treat Alzheimer's disease | PSEN1, PSEN2, BACE1 | TDP1 570/4885MAPK1 2079/4885ALDH1A1 165/4885 |
| US-11905301-B2 | Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals | NCL, NUDC, C3AR1 | TDP1 3518/4885MAPK1 4380/4885ALDH1A1 2338/4885 |
| US-20060276642-A1 | Compounds to treat Alzheimer's disease | PSEN2, PSEN1, BCHE | TDP1 1331/4885MAPK1 3711/4885ALDH1A1 311/4885 |
| US-20240190897-A1 | NITROGEN-CONTAINING MACROCYCLIC CONJUGATES AS RADIOPHARMACEUTICALS | NCL, NUDC, C3AR1 | TDP1 3518/4885MAPK1 4380/4885ALDH1A1 2338/4885 |
| US-20020128255-A1 | Compounds to treat alzheimer's disease | PSEN2, PSEN1, APP | TDP1 671/4885MAPK1 1871/4885ALDH1A1 391/4885 |
| US-20060287306-A1 | Compounds to treat alzheimer's disease | PSEN2, PSEN1, APP | TDP1 1064/4885MAPK1 3455/4885ALDH1A1 790/4885 |
| US-20030013881-A1 | Compounds to treat Alzheimer's disease | PSEN2, PSEN1, BACE1 | TDP1 589/4885MAPK1 2437/4885ALDH1A1 463/4885 |
| US-20020016320-A1 | Compounds to treat alzheimer's disease | PSEN1, PSEN2, CHAT | TDP1 979/4885MAPK1 3638/4885ALDH1A1 321/4885 |
| US-20020022623-A1 | Compounds to treat alzheimer's disease | PSEN1, PSEN2, BACE1 | TDP1 570/4885MAPK1 2079/4885ALDH1A1 165/4885 |
| US-20060211860-A1 | Compounds for the treatment of Alzheimer's disease | PSEN2, PSEN1, CHAT | TDP1 1316/4885MAPK1 4307/4885ALDH1A1 543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.